France CRISPR Market (2025-2030)
The France CRISPR Market was valued at $90.2 Million in 2025 and projected to reach to $152.1 Million by 2030, representing a compound annual growth rate of 11.0%. France's CRISPR market is poised for sustained expansion driven by its strong scientific foundation, government backing for precision medicine, and increasing private sector investment in gene-editing therapeutics.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
France CRISPR Market Trends and Insights
- Valued at $90.2 million in 2025, France is expected to expand to $152.1 million by 2030, reflecting an 11.0% compound annual growth rate.
- This expansion is driven by France's robust biotech infrastructure, government support for precision medicine initiatives, and increasing investment in genetic research facilities across the country. The French CRISPR market benefits from strong regulatory frameworks and collaborative research ecosystems that encourage both academic and commercial development.
- France's commitment to advancing therapeutic applications and diagnostic tools positions the nation as a competitive player in the European CRISPR sector.
- Between 2025 and 2030, France is anticipated to see accelerated adoption of CRISPR-based therapies, supported by healthcare system modernization and growing clinical trial activity throughout the country. France's market growth reflects broader European trends toward personalized medicine and gene therapy innovation.
- The country's strategic investments in life sciences and biotechnology clusters continue to attract international partnerships and venture capital, further strengthening France's role in the global CRISPR ecosystem..
Key Market Statistics
- CAGR (2025-2030) 11.0% CAGR
- Market Size, 2025 ~USD 90.2 Million
- Forecast, 2030 ~USD 152.1 Million
- Country France
France CRISPR Market Overview
Market Valuation :
France's CRISPR market is valued at $90.2 million in 2025, with projections reaching $152.1 million by 2030, representing significant growth potential in Europe's gene-editing sector.
Biotech Infrastructure :
France boasts a robust biotech ecosystem with leading research institutions, specialized clusters in Paris and Lyon, and established gene therapy manufacturing capabilities supporting CRISPR innovation.
Government Support :
French government initiatives prioritize precision medicine and genetic research funding, creating favorable regulatory pathways and investment incentives for CRISPR-based therapeutic development.
Growth Trajectory :
At 11.0% CAGR through 2030, France's CRISPR market growth aligns with global trends (11.2%), positioning the country as a stable and strategic hub for gene-editing commercialization in Europe.
France CRISPR Market Dynamics
- The country's regulatory framework, aligned with European standards, facilitates faster clinical trial approvals and market entry for innovative CRISPR solutions.
- Growing collaboration between academic institutions and biotech companies accelerates commercialization of genetic treatments for rare diseases and cancer applications. By 2030, France is expected to capture a larger share of European CRISPR revenues as healthcare systems increasingly adopt gene-editing therapies.
- Strategic partnerships with international biotech firms, coupled with domestic innovation hubs, will strengthen France's position as a key European player.
- Continued investment in R&D infrastructure and skilled workforce development will sustain the 11% annual growth rate, making France an attractive market for CRISPR therapeutics and diagnostics..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Key Takeaways
- France's CRISPR market is valued at $90.2 million in 2025 and is projected to reach $152.1 million by 2030, representing 68.6% growth over the forecast period.
- France maintains an 11.0% CAGR, demonstrating consistent market expansion driven by biotech infrastructure and government precision medicine support.
- France's regulatory environment and collaborative research ecosystems position the country as a competitive European hub for CRISPR innovation and clinical applications.
- France's strategic life sciences investments and venture capital attraction are accelerating CRISPR therapy adoption and diagnostic tool development through 2030.
CRISPR Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | GRNA SYNTHESIS & CELL LINE DEVELOPMENT (Service) |
| Forecast Period | 2025-2030 |
| Growth Rate | CAGR of 11.2% from 2025 to 2030 |
| Largest Segment | PRODUCT (Offering) |
| Market Size Base Year (Billions) | ~USD 3.22 (2025) |
| Revenue Forecast (Billions) | ~USD 5.47 (2030) |
| Segments Covered | Offering, Type, End User, Service, Application, Product |
France CRISPR Market Report Segmentation
6 segment dimensions are covered across the global market.
By Offering
- Product
- Products
- Service
- Services
By Type
- Crispr Kits & Enzymes
- Crispr Libraries
- Other Products
By End User
- Academic & Research Institutes
- Other End Users
- Pharmaceutical & Biotechnological Companies
- Pharmaceutical & Biotechnology Companies
By Service
- Grna Synthesis & Cell Line Development
- Other Services
- Screening & Validation
By Application
- Agriculture
- Drug Discovery & Development
- Other Applications
By Product
- Crispr Kits & Enzymes
- Crispr Libraries
- Other Products
FRANCE: CRISPR SERVICES MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 9.1 | 9.8 | 10.9 | 12.2 | 13.6 | 15.2 | 17 | 19 | 11.7 |
| OTHER END USERS | 9.9 | 10.7 | 11.8 | 13.1 | 14.5 | 16 | 17.7 | 19.7 | 10.8 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 12.1 | 13.1 | 14.6 | 16.4 | 18.3 | 20.5 | 23 | 25.8 | 12.1 |
| TOTAL | 31 | 33.6 | 37.3 | 41.7 | 46.4 | 51.7 | 57.7 | 64.5 | 11.5 |
FRANCE: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 20.7 | 21.7 | 24 | 26.6 | 29.5 | 32.7 | 36.3 | 40.3 | 10.9 |
| OTHER END USERS | 27.7 | 29.1 | 32.1 | 35.5 | 39.3 | 43.5 | 48.2 | 53.5 | 10.8 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 29.4 | 30.8 | 34.2 | 38 | 42.3 | 47 | 52.4 | 58.4 | 11.3 |
| TOTAL | 77.8 | 81.6 | 90.2 | 100.2 | 111 | 123.2 | 136.9 | 152.1 | 11 |
Target Audience
- Biotech & Pharma Companies : Manufacturers and developers of CRISPR therapeutics need France-specific market data to assess commercial viability, plan clinical trials, and establish manufacturing or distribution partnerships in this key European market.
- Investment & Venture Capital Firms : Investors evaluating European biotech opportunities require detailed France market analysis to identify promising CRISPR startups, assess growth potential, and make informed funding decisions in the region.
- Healthcare Policy & Government Bodies : French health authorities and policy makers use market intelligence to shape precision medicine strategies, allocate research funding, and develop regulatory frameworks supporting CRISPR innovation domestically.
- Research Institutions & Universities : Academic centers and research organizations need France market data to identify collaboration opportunities, secure funding, and understand commercialization pathways for their CRISPR research programs.
- Healthcare Providers & Hospital Systems : French hospitals and healthcare networks require market insights to evaluate CRISPR-based treatment adoption, budget for emerging therapies, and plan precision medicine service offerings for patients.
Reasons to Buy this Report
- Market-Specific Sizing : Access precise valuation data for France's CRISPR market with verified 2025 baseline ($90.2M) and 2030 forecasts ($152.1M), enabling accurate budget allocation and ROI projections for France-focused strategies.
- Competitive Landscape Intelligence : Understand France's unique biotech ecosystem, key players, research institutions, and government initiatives that differentiate the French market from other European regions and influence competitive positioning.
- Regulatory & Policy Insights : Gain detailed knowledge of French regulatory pathways, precision medicine initiatives, and government funding mechanisms that accelerate CRISPR commercialization and shape market entry strategies.
- Investment Opportunity Assessment : Evaluate France-specific growth drivers, market gaps, and emerging applications in rare diseases and oncology to identify high-potential investment targets and partnership opportunities within the country.
- Strategic Market Entry Planning : Leverage France-focused market data to develop localized go-to-market strategies, identify key stakeholders, and optimize resource allocation for successful CRISPR product launches in the French market.
Frequently asked questions
What is the current size of the CRISPR market in France?
France's CRISPR market is valued at $90.2 million in 2025, with expectations to grow to $152.1 million by 2030.
What is the projected growth rate for France's CRISPR market?
France's CRISPR market is expected to grow at an 11.0% compound annual growth rate (CAGR) from 2025 to 2030.
What factors are driving CRISPR market growth in France?
France's CRISPR market growth is driven by robust biotech infrastructure, government support for precision medicine, increased research facility investment, and expanding clinical trial activity.
How does France's CRISPR market compare to other European markets?
France is positioned as a key European hub for CRISPR innovation, supported by strong regulatory frameworks, collaborative research ecosystems, and strategic life sciences investments that attract international partnerships.
What applications are driving CRISPR adoption in France?
France's CRISPR market is expanding through therapeutic applications, diagnostic tools, and personalized medicine initiatives supported by healthcare system modernization and clinical trial infrastructure.
RESEARCH METHODOLOGY
The research study utilized a range of secondary sources, directories, and databases to gather important information for analyzing the global CRISPR market. In addition, extensive interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level executives from leading market players, and industry consultants. These interviews helped obtain and verify qualitative and quantitative information, allowing for a comprehensive evaluation of the market's growth scenarios. The global market size was estimated through secondary research, using both top-down and bottom-up approaches, followed by data triangulation that incorporated insights from industry experts to determine the final market size.
Secondary Research
Secondary research was primarily utilized to identify and gather information for the technical, market-oriented, and commercial analysis of the CRISPR market. The sources consulted for this study included the Broad Institute, Innovative Genomics Institute (IGI), National Institute of Food and Agriculture, International Chromosome and Genome Society (ICGS), National Human Genome Research Institute (NHGRI), Asia Pacific Society of Human Genetics (APSHG), Genetics Society of America (GSA), European Society of Human Genetics (ESHG), Centers for Common Disease Genomics (CDDG), Center for Cellular and Molecular Biology (CCMB) in India, and the Department of Biotechnology (DBT) in India.
Additional secondary sources comprised academic journals, company websites, corporate and regulatory filings such as annual reports, SEC filings, investor presentations, and financial statements; business magazines and research journals; press releases; and various trade, business, and professional associations. These sources were also instrumental in gathering essential information about key market players, market segmentation related to industry trends, developments at the regional and country levels, and technology prospects.
The secondary data collected was analyzed to determine the global CRISPR market size, which was subsequently validated through primary research.
Primary Research
Extensive primary research was conducted after gathering foundational knowledge about the global CRISPR market through secondary research. We carried out several primary interviews with market experts from both the demand and supply sides. On the demand side, we interviewed professionals from the pharmaceutical and biopharmaceutical industries, as well as from contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). On the supply side, we spoke with C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners.
The primary interviews were conducted across six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 65% of the interviews involved supply-side participants, while 35% were with demand-side participants. This primary data was collected through questionnaires, emails, online surveys, personal interviews, and telephone interviews.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were utilized to estimate and validate the overall size of the CRISPR market. These methods were also extensively employed to assess the sizes of various subsegments within the market. The research methodology for estimating the market size includes the following steps:
CRISPR Market : Top-Down and Bottom-Up Approach
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is a revolutionary tool used to edit genes in a way that resembles traditional GMO techniques. The use of the Cas9 enzymes differentiates CRISPR from other forms of genetic modification. CRISPR edits and rearranges genes by cutting out the damaged or unwanted part of the DNA, allowing the remaining DNA to be rearranged in a new way.
The report comprehensively analyzes the CRISPR market, covering a wide range of products & services such as CRISPR kits & enzymes, CRISPR libraries, gRNA synthesis, cell line development, and screening & validation.
Key Stakeholders
- Genome editing/genome engineering product manufacturers
- CRISPR editing/genome engineering product manufacturers
- Suppliers and distributors of genomic instruments/systems and consumables
- Contract manufacturing organizations
- Pharmaceutical and biotechnology companies
- Diagnostic centers and medical colleges
- Contract research organizations
- Government associations and research institutes
- Regulatory authorities
- Business research firms
Report Objectives
- To define, describe, and forecast the CRISPR market by offering, product, service, application, end user (products market), end user (services market), and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall CRISPR market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product/service launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Portfolio Assessment
- Product Matrix, which gives a detailed comparison of the product/service portfolios of the top three companies.
Company Information
- Detailed analysis and profiling of additional market players (up to three).
Geographical Analysis
- A further breakdown of the Rest of Asia Pacific CRISPR market into countries
- A further breakdown of the Rest of Europe CRISPR market into countries
- A further breakdown of the Rest of Latin America CRISPR market into countries
Get the Full CRISPR Market Report
Full forecast, segment splits, and company analysis for all CRISPR Market.
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report